360Dx

Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

Sep 24, 2019

This article has been updated with financial and other details from a Natera regulatory filing.

NEW YORK – Foundation Medicine and Natera said today that they will jointly develop and commercialize personalized circulating tumor DNA monitoring assays for biopharmaceutical and clinical customers who order the FoundationOne CDx test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

To read the full story....

Breaking News

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

OpGen Unyvero IVD Platform Nabs Chinese Regulatory Approval

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

What's Popular?

Hologic Acquires European MDx Firm Diagenode for Approximately $159M

Reference Labs Take Diverse Approaches to Mitigating COVID-19 Sample Shipping Delays

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Bio-Techne Obtains Reimbursement Contract With Humana for Exosome Diagnostics Prostate Biopsy Test

Sponsorships